Syros Pharmaceuticals Inc. (SYRS) Company Profile & Statistics

Syros Pharmaceuticals Inc.
SYRS
(Nasdaq - US)
N/A
5.37
-0.01 (-0.19%)
in:usd•As of: Apr 30, 2024 15:59 UTC -4
Open
5.31
High
5.41
Low
5.24

About Syros Pharmaceuticals Inc.

CEO

Conley Chee

Headquarters

35 cambridge park drive, 4th floor

cambridge, ma 02140, united states

Auditor

Ernst & Young LLP

Employees

Share Holders

Website

www.syros.com

Industry

biotechnology

Sector

health technology

Company Overview

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

Syros Pharmaceuticals Inc. Statistics

Valuation Measures

Market Capitalization ²	143.54M
Enterprise Value	45.24M
Enterprise Value/EBITDA (ttm)	-0.36
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	6.37
Price to Sales (ttm)	13.56
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-1335.85%
Profit Margin (ttm)	-4947.23%
Return on Equity (ttm)	-227.91%
Return on Invested Capital (ttm)	-226.80%
Return on Assets (ttm)	-75.60%

Income Statement

Revenue (ttm)	9.94M
Revenue Per Share (ttm)	0.38
Gross Profit (ttm)	9.94M
EBITDA (ttm)³	-126.16M
Net Income Avi to Common (ttm)	-164.57M
Diluted EPS (ttm)	-5.76

Share Statistics

Beta (5Y Monthly)	1.75
52-Week Change	65.74%
S&P500 52-Week Change	24.15%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	26.45M
Dividend Yield	0.00%
Float ⁴	23.93M
% Held by Insiders	10.45%
% Held by Institutions	91.47%

Balance Sheet

Total Cash (mrq)	139.53M
Total Cash Per Share (mrq)	5.27
Total Debt (mrq)	41.22M
Total Debt/Equity (mrq)	247.41%
Current Ratio (mrq)	3.95%
Quick Ratio (mrq)	3.95%
Book Value Per Share (mrq)	0.63

Cash Flow

Operating Cash Flow Per Share (ytd)	-3.87
Free Cash Flow (ytd)	-108.42M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Syros Pharmaceuticals Inc.

Trade With A Regulated Broker